AwardTape · Defense awards · Glyphic Biotechnologies, Inc
Glyphic Biotechnologies, Inc: $250K in DoD and DHS awards
Glyphic Biotechnologies, Inc holds 1 DoD and DHS prime award with $250K obligated Apr 8, 2024 to Apr 8, 2024. Largest category: Health R&D at $250K; largest buyer: Defense Health Agency at $250K.
| Obligated FY2024+ | $250K |
|---|---|
| Awards | 1 |
| FY2024 | $250K |
| FY2025 | $0 |
| FY2026 to date | $0 |
| Lifetime obligated on these awards | $250K |
| Parent company (as reported) | Glyphic Biotechnologies, Inc |
| First and latest action | Apr 8, 2024 · Apr 8, 2024 |
| # | Category | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Health R&D | $250K | 1 awards | 100% |
| # | Agency | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Defense Health Agency | $250K | 1 awards | 100% |
| Award | Obligated FY2024+ | What | Agency | Category | Latest action |
|---|---|---|---|---|---|
| HT942524P0042 purchase order | $250K | Medical r and d purchase order for a DHA sttr phase i, proposal no. h23c-001-0042, titled, "development of anti-glycan antibodies against multi-drug resistant eskape wound pathogens" | Defense Health Agency | Health R&D | Apr 8, 2024 DoD 90d |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Data as of Oct 9, 2026.
Terminal: filters, alerts and CSV export for this company's awards.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial